thanks gestalt - that's very helpful. clearly you have a lot more knowledge in this space than i do (of course, that's a low bar) .

that being the case, when you look at the NASH data that was released at the conference, it is your opinion that this data is good enough to be a catalyst for a partnership with a legitimate player (a Gilead, GSK, PFE, etc.)?

it sure would be great to be down the road in those discussions already. I just have no ability to gague these results, and if they are strong enough to motivate a big player to sign us up.